Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
39.38
-0.05 (-0.13%)
Oct 30, 2025, 9:37 AM EDT - Market open
Exelixis Revenue
Exelixis had revenue of $568.26M in the quarter ending June 30, 2025, a decrease of -10.82%. This brings the company's revenue in the last twelve months to $2.23B, up 10.73% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+10.73%
P/S Ratio
4.96
Revenue / Employee
$1,944,207
Employees
1,147
Market Cap
10.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EXEL News
- 8 days ago - Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire
- 9 days ago - Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results - Benzinga
- 10 days ago - Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet - Business Wire
- 12 days ago - Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 - Business Wire
- 5 weeks ago - Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 7 weeks ago - Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire